KnotesFree Orthopaedic & FRCS notes, viva stations and higher order SBAs

Glucosamine and chondroitin

High YieldApplied Basic SciencesthinKbox SBA

Overview

Glucosamine and chondroitin are dietary supplements marketed for symptomatic osteoarthritis, particularly knee osteoarthritis. They are structural constituents or precursors related to cartilage extracellular matrix, but this does not establish a clinically important disease-modifying effect when taken orally.

Proposed actions

Glucosamine

Proposed effects include substrate provision for glycosaminoglycan synthesis and modulation of inflammatory pathways.

Chondroitin sulphate

Proposed effects include support of proteoglycan structure and possible anti-inflammatory effects.

Evidence in osteoarthritis

Clinical trials have produced inconsistent results. Some studies report small improvements in pain or function, while others show little or no clinically important benefit compared with placebo.

The apparent effect may differ between pharmaceutical-grade preparations and over-the-counter products because formulation and purity vary.

Disease modification

There is no consistent evidence that glucosamine or chondroitin reliably restores articular cartilage or prevents progression of established osteoarthritis.

Practical interpretation

  • They should not replace established non-operative treatment such as exercise, weight management, appropriate analgesia and activity modification.
  • If a patient chooses to try them, benefit should be judged by symptoms over a defined trial period.
  • Treatment should be stopped if there is no meaningful improvement.

Adverse effects and caution

Generally well tolerated, but gastrointestinal symptoms may occur. Check for interactions, allergy and comorbidity before use.

References

  1. Major osteoarthritis guidelines and systematic reviews on glucosamine and chondroitin.

Written/reviewed by Kishore Puthezhath

Professor of Orthopaedics and Consultant Paediatric Orthopaedic Surgeon

FRCS (Tr & Orth) revision resource

Reviewed: September 2026